Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00321412 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas
A Phase 3 study, sponsored by Ocera Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 191
- Enrollment target
NCT00321412 is a Phase 3 study that has completed, run by Ocera Therapeutics. The registered enrollment target is 191 participants.
The verdict
NCT00321412, a Phase 3 study, has completed, sponsored by Ocera Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 191 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 in treating patients with mild to moderately severe Crohn's disease who have fistulas. The study will test whether or not patients receiving AST-120 experience a greater reduction in number of draining fistulas and improvement of their other Crohn's disease symptoms versus patients who receive placebo (material that does not contain any active medication).
Interventions
- DRUG AST-120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00321412
The ClinicalTrials.gov registry entry for NCT00321412 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocera Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AST-120 is the first listed.
NCT00321412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00321412 about?
NCT00321412 is a clinical study titled "Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas". The objective of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 in treating patients with mild to moderately severe Crohn's disease who have fistulas. The study will test whether or not patients receiving AST-120 experience a greater reduction in number of dr...
What is the current status of trial NCT00321412?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 191 participants. The study started on 2006-03. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00321412?
The interventions under investigation include: AST-120 (DRUG).
Who is sponsoring clinical trial NCT00321412?
This trial is sponsored by Ocera Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.